PDF(Pubmed)
Abstract：
UNASSIGNED: Hypofibrinogenemia is a serious adverse reaction related to tigecycline administered against multidrug-resistant (MDR) bacteria and can lead to therapy termination. High dose and prolonged tigecycline therapy, renal failure, and base level of fibrinogen (FIB) were reported risk factors of tigecycline-associated FIB reduction. But results are unknown in patients with renal transplantation.
UNASSIGNED: A single-center and a case-control study involving renal transplantation patients was conducted. From January, 2017 to January, 2020, patients with a tigecycline course more than 2 days and a baseline FIB level greater than 2 g/L were enrolled. Hypofibrinogenemia was defined as plasma FIB <2.0 g/L. The extent of FIB reduction was calculated based on the baseline of FIB level before tigecycline administration. FIBRO was defined as the extent of FIB reduction over 50%, and FIBRB referred to the extent of FIB reduction below 50%. Univariate and multivariate analyses were performed by logistic regression models to identify independent risk factors of tigecycline-associated FIB reduction.
UNASSIGNED: In total, 120 patients were enrolled. A total of 114 patients (95.00%) developed with hypofibrinogenaemia. Hypofibrinogenemia mainly occurred 3 days after tigecycline administration. Of them, 79 (65.83%) developed FIBRO with a median occurrence of 3 [2-4] days after initiation of tigecycline. Multivariable regression analysis demonstrated that the FIB level before tigecycline use [odds ratio (OR): 3.225, 95% confidence interval (CI): 1.801-5.772] and total tigecycline dose (OR: 4.930, 95% CI: 1.433-16.959) were risk factors for FIBRO.
UNASSIGNED: The FIB level before tigecycline use and total tigecycline dose were significantly associated with FIBRO, suggesting that FIB level and coagulation-related indicators should be closely monitored during tigecycline treatment to avoid life-threatening bleeding events.
UNASSIGNED: A single-center and a case-control study involving renal transplantation patients was conducted. From January, 2017 to January, 2020, patients with a tigecycline course more than 2 days and a baseline FIB level greater than 2 g/L were enrolled. Hypofibrinogenemia was defined as plasma FIB <2.0 g/L. The extent of FIB reduction was calculated based on the baseline of FIB level before tigecycline administration. FIBRO was defined as the extent of FIB reduction over 50%, and FIBRB referred to the extent of FIB reduction below 50%. Univariate and multivariate analyses were performed by logistic regression models to identify independent risk factors of tigecycline-associated FIB reduction.
UNASSIGNED: In total, 120 patients were enrolled. A total of 114 patients (95.00%) developed with hypofibrinogenaemia. Hypofibrinogenemia mainly occurred 3 days after tigecycline administration. Of them, 79 (65.83%) developed FIBRO with a median occurrence of 3 [2-4] days after initiation of tigecycline. Multivariable regression analysis demonstrated that the FIB level before tigecycline use [odds ratio (OR): 3.225, 95% confidence interval (CI): 1.801-5.772] and total tigecycline dose (OR: 4.930, 95% CI: 1.433-16.959) were risk factors for FIBRO.
UNASSIGNED: The FIB level before tigecycline use and total tigecycline dose were significantly associated with FIBRO, suggesting that FIB level and coagulation-related indicators should be closely monitored during tigecycline treatment to avoid life-threatening bleeding events.
摘要：
未经证实：低血纤维蛋白原血症是与替加环素抗多药耐药(MDR)细菌相关的严重不良反应，可导致治疗终止。大剂量和延长替加环素治疗，肾功能衰竭,纤维蛋白原基础水平（FIB）是替加环素相关FIB降低的危险因素。但肾移植患者的结果未知。
UNASSIGNED：进行了一项涉及肾移植患者的单中心和病例对照研究。从1月起,2017年1月,2020年，替加环素疗程超过2天且基线FIB水平大于2g/L的患者入组。低纤维蛋白原血症定义为血浆FIB<2.0g/L。基于替加环素给药前FIB水平的基线计算FIB降低的程度。FIBRO被定义为FIB减少超过50%的程度，和FIBRB是指FIB减少低于50%的程度。通过Logistic回归模型进行单变量和多变量分析，以确定替加环素相关FIB降低的独立危险因素。
未经批准：总共，纳入120例患者。共有114例患者（95.00％）出现了低纤维蛋白原血症。低纤维蛋白原血症主要发生在替加环素给药后3天。其中,79（65.83％）在替加环素开始后3[2-4]天出现FIBRO。多因素回归分析显示，替加环素使用前的FIB水平[比值比（OR）：3.225，95％置信区间（CI）：1.801-5.772]和替加环素总剂量（OR：4.930，95％CI：1.433-16.959）是FIBRO的危险因素。
UNASSIGNED：使用替加环素前的FIB水平和替加环素总剂量与FIBRO显着相关，提示在替加环素治疗期间应密切监测FIB水平和凝血相关指标,以避免危及生命的出血事件.
UNASSIGNED：进行了一项涉及肾移植患者的单中心和病例对照研究。从1月起,2017年1月,2020年，替加环素疗程超过2天且基线FIB水平大于2g/L的患者入组。低纤维蛋白原血症定义为血浆FIB<2.0g/L。基于替加环素给药前FIB水平的基线计算FIB降低的程度。FIBRO被定义为FIB减少超过50%的程度，和FIBRB是指FIB减少低于50%的程度。通过Logistic回归模型进行单变量和多变量分析，以确定替加环素相关FIB降低的独立危险因素。
未经批准：总共，纳入120例患者。共有114例患者（95.00％）出现了低纤维蛋白原血症。低纤维蛋白原血症主要发生在替加环素给药后3天。其中,79（65.83％）在替加环素开始后3[2-4]天出现FIBRO。多因素回归分析显示，替加环素使用前的FIB水平[比值比（OR）：3.225，95％置信区间（CI）：1.801-5.772]和替加环素总剂量（OR：4.930，95％CI：1.433-16.959）是FIBRO的危险因素。
UNASSIGNED：使用替加环素前的FIB水平和替加环素总剂量与FIBRO显着相关，提示在替加环素治疗期间应密切监测FIB水平和凝血相关指标,以避免危及生命的出血事件.
